Effects of Pamidronate on Bone Metastases
Author Information
Author(s): J Vinholes, C-Y Guo, OP Purohit, R Eastell, RE Coleman
Primary Institution: University of Sheffield
Hypothesis
Pamidronate will effectively reduce bone resorption markers in patients with metastatic bone disease.
Conclusion
Pamidronate significantly reduces bone resorption markers and provides pain relief in patients with metastatic bone disease.
Supporting Evidence
- Pamidronate induced a significant fall in bone resorption markers.
- 70% of patients had increased deoxypyridinoline levels before treatment.
- Biochemical responders had a mean reduction in pain score of about 30%.
Takeaway
Pamidronate helps people with cancer that has spread to their bones by reducing pain and lowering certain markers in the body that show how much bone is being broken down.
Methodology
Twenty patients received a single infusion of pamidronate and were evaluated at baseline, 2, 4, and 8 weeks after treatment, with various biochemical markers measured.
Potential Biases
Potential bias due to the lack of a control group and the subjective nature of pain assessment.
Limitations
The study had a small sample size and was limited to patients with specific types of bone metastases.
Participant Demographics
15 women with breast cancer, 3 men with prostate cancer, and 2 others; mean age 48 years.
Statistical Information
P-Value
p<0.017
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website